Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume
Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low‐Density Lipoprotein (LDL) cholesterol. On the other hand, High‐Density Lipoproteins (HDL) cholesterol levels have been associ...
Gespeichert in:
Veröffentlicht in: | Journal of neurochemistry 2022-10, Vol.163 (1), p.53-67 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 67 |
---|---|
container_issue | 1 |
container_start_page | 53 |
container_title | Journal of neurochemistry |
container_volume | 163 |
creator | Pedrini, Steve Doecke, James D. Hone, Eugene Wang, Penghao Thota, Rohith Bush, Ashley I. Rowe, Christopher C. Dore, Vincent Villemagne, Victor L. Ames, David Rainey‐Smith, Stephanie Verdile, Giuseppe Sohrabi, Hamid R. Raida, Manfred R. Taddei, Kevin Gandy, Sam Masters, Colin L. Chatterjee, Pratishtha Martins, Ralph N. |
description | Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low‐Density Lipoprotein (LDL) cholesterol. On the other hand, High‐Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL‐functionality, which depends upon the HDL‐cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL‐cargo (Cholesterol, ApoA‐I, ApoA‐II, ApoC‐I, ApoC‐III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC‐Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA‐I ratio in AD and HC‐Conv, as well as an increased ApoD/ApoA‐I ratio and a decreased ApoA‐II/ApoA‐I ratio in AD. Higher cholesterol/ApoA‐I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA‐II/ApoA‐I and ApoJ/ApoA‐I ratios were associated with greater cortical grey matter volume (and for ApoA‐II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status‐independent manner, the ApoE/ApoA‐I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
Remodeling of high‐density lipoprotein (HDL) during disease onset and progression, in which cholesterol and Apolipoprotein D levels are increased while Apolipoprotein A‐II levels are decreased on HDL (left). Additionally, increased cholesterol levels on HDL are associated with increased ventricular volume and decreased grey matter volume, while increased levels of Apolipoprotein A‐II and Apolipoprotein J are associated with increased hippocampal and grey matter volume and reduced ventricular volume (right). |
doi_str_mv | 10.1111/jnc.15681 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9804612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2718476613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4431-90f73bb633b6322f0f97d8d8491af2141a28d66e11e0045b08ca986df3c09b8f3</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy0EokvhwAsgSxyAQ9qx43WcC1K1ovxRBRzgbDnOZOOVEy92stVy4hF4xj4JbrdUgISlkSXP509j_wh5yuCE5XW6Ge0JW0rF7pEFExUrBFvW98kCgPOiBMGPyKOUNgBMCskekqNSAsCSqwXZffYmDYb2bt1f_fjZ4pjctKfebcM2hgndSK2J60BdosZPGLGl-ezMf-_RDRhfJNq6hCYhNWN7Q6UUrDNTBi_d1NOIaxdG42kTTb65C34e8DF50Bmf8Mntfky-nr_5snpXXHx6-351dlFYIUpW1NBVZdPIsszFeQddXbWqVaJmpuNMMMNVKyUyhgBi2YCyplay7UoLdaO68pi8Pni3czNga3GcovF6G91g4l4H4_TfndH1eh12ulaQv4pnwctbQQzfZkyTHlyy6L0ZMcxJ8wokUyAFZPT5P-gmzDG__JpiSlRSsjJTrw6UjSGliN3dMAz0dZo6p6lv0szssz-nvyN_x5eB0wNw6Tzu_2_SHz6uDspfyQarkg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718476613</pqid></control><display><type>article</type><title>Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>IngentaConnect Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Free Full-Text Journals in Chemistry</source><creator>Pedrini, Steve ; Doecke, James D. ; Hone, Eugene ; Wang, Penghao ; Thota, Rohith ; Bush, Ashley I. ; Rowe, Christopher C. ; Dore, Vincent ; Villemagne, Victor L. ; Ames, David ; Rainey‐Smith, Stephanie ; Verdile, Giuseppe ; Sohrabi, Hamid R. ; Raida, Manfred R. ; Taddei, Kevin ; Gandy, Sam ; Masters, Colin L. ; Chatterjee, Pratishtha ; Martins, Ralph N.</creator><creatorcontrib>Pedrini, Steve ; Doecke, James D. ; Hone, Eugene ; Wang, Penghao ; Thota, Rohith ; Bush, Ashley I. ; Rowe, Christopher C. ; Dore, Vincent ; Villemagne, Victor L. ; Ames, David ; Rainey‐Smith, Stephanie ; Verdile, Giuseppe ; Sohrabi, Hamid R. ; Raida, Manfred R. ; Taddei, Kevin ; Gandy, Sam ; Masters, Colin L. ; Chatterjee, Pratishtha ; Martins, Ralph N. ; AIBL Research Group ; the AIBL Research Group</creatorcontrib><description>Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low‐Density Lipoprotein (LDL) cholesterol. On the other hand, High‐Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL‐functionality, which depends upon the HDL‐cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL‐cargo (Cholesterol, ApoA‐I, ApoA‐II, ApoC‐I, ApoC‐III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC‐Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA‐I ratio in AD and HC‐Conv, as well as an increased ApoD/ApoA‐I ratio and a decreased ApoA‐II/ApoA‐I ratio in AD. Higher cholesterol/ApoA‐I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA‐II/ApoA‐I and ApoJ/ApoA‐I ratios were associated with greater cortical grey matter volume (and for ApoA‐II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status‐independent manner, the ApoE/ApoA‐I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
Remodeling of high‐density lipoprotein (HDL) during disease onset and progression, in which cholesterol and Apolipoprotein D levels are increased while Apolipoprotein A‐II levels are decreased on HDL (left). Additionally, increased cholesterol levels on HDL are associated with increased ventricular volume and decreased grey matter volume, while increased levels of Apolipoprotein A‐II and Apolipoprotein J are associated with increased hippocampal and grey matter volume and reduced ventricular volume (right).</description><identifier>ISSN: 0022-3042</identifier><identifier>EISSN: 1471-4159</identifier><identifier>DOI: 10.1111/jnc.15681</identifier><identifier>PMID: 36000528</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Alzheimer Disease ; Alzheimer's disease ; Amyloidosis ; amyloid‐β ; ApoE ; Apolipoprotein A-I - metabolism ; Apolipoprotein A-II - metabolism ; Apolipoprotein C-III - metabolism ; Apolipoprotein E ; Apolipoprotein E4 - metabolism ; Apolipoproteins E - metabolism ; Brain ; Brain - metabolism ; Cargo ; Cholesterol ; Cholesterol - metabolism ; Cognitive ability ; Density ; HDL ; HDL‐cargo ; High density lipoprotein ; Hippocampus ; Humans ; Lipoproteins ; Lipoproteins, HDL - metabolism ; Lipoproteins, LDL - metabolism ; Low density lipoprotein ; Neurodegenerative diseases ; Original ; ORIGINAL ARTICLES ; Patients ; Substantia grisea ; Ventricle</subject><ispartof>Journal of neurochemistry, 2022-10, Vol.163 (1), p.53-67</ispartof><rights>2022 The Authors. published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.</rights><rights>2022 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4431-90f73bb633b6322f0f97d8d8491af2141a28d66e11e0045b08ca986df3c09b8f3</citedby><cites>FETCH-LOGICAL-c4431-90f73bb633b6322f0f97d8d8491af2141a28d66e11e0045b08ca986df3c09b8f3</cites><orcidid>0000-0003-2863-0293 ; 0000-0001-6708-3718 ; 0000-0001-8259-9069 ; 0000-0003-3072-7940 ; 0000-0003-4877-1958 ; 0000-0002-6409-8022 ; 0000-0003-2475-0124 ; 0000-0001-7328-9624 ; 0000-0001-8017-8682 ; 0000-0002-8106-7957 ; 0000-0002-8051-0558 ; 0000-0002-0293-913X ; 0000-0003-3910-2453 ; 0000-0002-4828-9363</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjnc.15681$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjnc.15681$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,1434,27928,27929,45578,45579,46413,46837</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36000528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pedrini, Steve</creatorcontrib><creatorcontrib>Doecke, James D.</creatorcontrib><creatorcontrib>Hone, Eugene</creatorcontrib><creatorcontrib>Wang, Penghao</creatorcontrib><creatorcontrib>Thota, Rohith</creatorcontrib><creatorcontrib>Bush, Ashley I.</creatorcontrib><creatorcontrib>Rowe, Christopher C.</creatorcontrib><creatorcontrib>Dore, Vincent</creatorcontrib><creatorcontrib>Villemagne, Victor L.</creatorcontrib><creatorcontrib>Ames, David</creatorcontrib><creatorcontrib>Rainey‐Smith, Stephanie</creatorcontrib><creatorcontrib>Verdile, Giuseppe</creatorcontrib><creatorcontrib>Sohrabi, Hamid R.</creatorcontrib><creatorcontrib>Raida, Manfred R.</creatorcontrib><creatorcontrib>Taddei, Kevin</creatorcontrib><creatorcontrib>Gandy, Sam</creatorcontrib><creatorcontrib>Masters, Colin L.</creatorcontrib><creatorcontrib>Chatterjee, Pratishtha</creatorcontrib><creatorcontrib>Martins, Ralph N.</creatorcontrib><creatorcontrib>AIBL Research Group</creatorcontrib><creatorcontrib>the AIBL Research Group</creatorcontrib><title>Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume</title><title>Journal of neurochemistry</title><addtitle>J Neurochem</addtitle><description>Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low‐Density Lipoprotein (LDL) cholesterol. On the other hand, High‐Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL‐functionality, which depends upon the HDL‐cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL‐cargo (Cholesterol, ApoA‐I, ApoA‐II, ApoC‐I, ApoC‐III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC‐Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA‐I ratio in AD and HC‐Conv, as well as an increased ApoD/ApoA‐I ratio and a decreased ApoA‐II/ApoA‐I ratio in AD. Higher cholesterol/ApoA‐I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA‐II/ApoA‐I and ApoJ/ApoA‐I ratios were associated with greater cortical grey matter volume (and for ApoA‐II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status‐independent manner, the ApoE/ApoA‐I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
Remodeling of high‐density lipoprotein (HDL) during disease onset and progression, in which cholesterol and Apolipoprotein D levels are increased while Apolipoprotein A‐II levels are decreased on HDL (left). Additionally, increased cholesterol levels on HDL are associated with increased ventricular volume and decreased grey matter volume, while increased levels of Apolipoprotein A‐II and Apolipoprotein J are associated with increased hippocampal and grey matter volume and reduced ventricular volume (right).</description><subject>Alzheimer Disease</subject><subject>Alzheimer's disease</subject><subject>Amyloidosis</subject><subject>amyloid‐β</subject><subject>ApoE</subject><subject>Apolipoprotein A-I - metabolism</subject><subject>Apolipoprotein A-II - metabolism</subject><subject>Apolipoprotein C-III - metabolism</subject><subject>Apolipoprotein E</subject><subject>Apolipoprotein E4 - metabolism</subject><subject>Apolipoproteins E - metabolism</subject><subject>Brain</subject><subject>Brain - metabolism</subject><subject>Cargo</subject><subject>Cholesterol</subject><subject>Cholesterol - metabolism</subject><subject>Cognitive ability</subject><subject>Density</subject><subject>HDL</subject><subject>HDL‐cargo</subject><subject>High density lipoprotein</subject><subject>Hippocampus</subject><subject>Humans</subject><subject>Lipoproteins</subject><subject>Lipoproteins, HDL - metabolism</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Low density lipoprotein</subject><subject>Neurodegenerative diseases</subject><subject>Original</subject><subject>ORIGINAL ARTICLES</subject><subject>Patients</subject><subject>Substantia grisea</subject><subject>Ventricle</subject><issn>0022-3042</issn><issn>1471-4159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQhy0EokvhwAsgSxyAQ9qx43WcC1K1ovxRBRzgbDnOZOOVEy92stVy4hF4xj4JbrdUgISlkSXP509j_wh5yuCE5XW6Ge0JW0rF7pEFExUrBFvW98kCgPOiBMGPyKOUNgBMCskekqNSAsCSqwXZffYmDYb2bt1f_fjZ4pjctKfebcM2hgndSK2J60BdosZPGLGl-ezMf-_RDRhfJNq6hCYhNWN7Q6UUrDNTBi_d1NOIaxdG42kTTb65C34e8DF50Bmf8Mntfky-nr_5snpXXHx6-351dlFYIUpW1NBVZdPIsszFeQddXbWqVaJmpuNMMMNVKyUyhgBi2YCyplay7UoLdaO68pi8Pni3czNga3GcovF6G91g4l4H4_TfndH1eh12ulaQv4pnwctbQQzfZkyTHlyy6L0ZMcxJ8wokUyAFZPT5P-gmzDG__JpiSlRSsjJTrw6UjSGliN3dMAz0dZo6p6lv0szssz-nvyN_x5eB0wNw6Tzu_2_SHz6uDspfyQarkg</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Pedrini, Steve</creator><creator>Doecke, James D.</creator><creator>Hone, Eugene</creator><creator>Wang, Penghao</creator><creator>Thota, Rohith</creator><creator>Bush, Ashley I.</creator><creator>Rowe, Christopher C.</creator><creator>Dore, Vincent</creator><creator>Villemagne, Victor L.</creator><creator>Ames, David</creator><creator>Rainey‐Smith, Stephanie</creator><creator>Verdile, Giuseppe</creator><creator>Sohrabi, Hamid R.</creator><creator>Raida, Manfred R.</creator><creator>Taddei, Kevin</creator><creator>Gandy, Sam</creator><creator>Masters, Colin L.</creator><creator>Chatterjee, Pratishtha</creator><creator>Martins, Ralph N.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2863-0293</orcidid><orcidid>https://orcid.org/0000-0001-6708-3718</orcidid><orcidid>https://orcid.org/0000-0001-8259-9069</orcidid><orcidid>https://orcid.org/0000-0003-3072-7940</orcidid><orcidid>https://orcid.org/0000-0003-4877-1958</orcidid><orcidid>https://orcid.org/0000-0002-6409-8022</orcidid><orcidid>https://orcid.org/0000-0003-2475-0124</orcidid><orcidid>https://orcid.org/0000-0001-7328-9624</orcidid><orcidid>https://orcid.org/0000-0001-8017-8682</orcidid><orcidid>https://orcid.org/0000-0002-8106-7957</orcidid><orcidid>https://orcid.org/0000-0002-8051-0558</orcidid><orcidid>https://orcid.org/0000-0002-0293-913X</orcidid><orcidid>https://orcid.org/0000-0003-3910-2453</orcidid><orcidid>https://orcid.org/0000-0002-4828-9363</orcidid></search><sort><creationdate>202210</creationdate><title>Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume</title><author>Pedrini, Steve ; Doecke, James D. ; Hone, Eugene ; Wang, Penghao ; Thota, Rohith ; Bush, Ashley I. ; Rowe, Christopher C. ; Dore, Vincent ; Villemagne, Victor L. ; Ames, David ; Rainey‐Smith, Stephanie ; Verdile, Giuseppe ; Sohrabi, Hamid R. ; Raida, Manfred R. ; Taddei, Kevin ; Gandy, Sam ; Masters, Colin L. ; Chatterjee, Pratishtha ; Martins, Ralph N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4431-90f73bb633b6322f0f97d8d8491af2141a28d66e11e0045b08ca986df3c09b8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alzheimer Disease</topic><topic>Alzheimer's disease</topic><topic>Amyloidosis</topic><topic>amyloid‐β</topic><topic>ApoE</topic><topic>Apolipoprotein A-I - metabolism</topic><topic>Apolipoprotein A-II - metabolism</topic><topic>Apolipoprotein C-III - metabolism</topic><topic>Apolipoprotein E</topic><topic>Apolipoprotein E4 - metabolism</topic><topic>Apolipoproteins E - metabolism</topic><topic>Brain</topic><topic>Brain - metabolism</topic><topic>Cargo</topic><topic>Cholesterol</topic><topic>Cholesterol - metabolism</topic><topic>Cognitive ability</topic><topic>Density</topic><topic>HDL</topic><topic>HDL‐cargo</topic><topic>High density lipoprotein</topic><topic>Hippocampus</topic><topic>Humans</topic><topic>Lipoproteins</topic><topic>Lipoproteins, HDL - metabolism</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Low density lipoprotein</topic><topic>Neurodegenerative diseases</topic><topic>Original</topic><topic>ORIGINAL ARTICLES</topic><topic>Patients</topic><topic>Substantia grisea</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pedrini, Steve</creatorcontrib><creatorcontrib>Doecke, James D.</creatorcontrib><creatorcontrib>Hone, Eugene</creatorcontrib><creatorcontrib>Wang, Penghao</creatorcontrib><creatorcontrib>Thota, Rohith</creatorcontrib><creatorcontrib>Bush, Ashley I.</creatorcontrib><creatorcontrib>Rowe, Christopher C.</creatorcontrib><creatorcontrib>Dore, Vincent</creatorcontrib><creatorcontrib>Villemagne, Victor L.</creatorcontrib><creatorcontrib>Ames, David</creatorcontrib><creatorcontrib>Rainey‐Smith, Stephanie</creatorcontrib><creatorcontrib>Verdile, Giuseppe</creatorcontrib><creatorcontrib>Sohrabi, Hamid R.</creatorcontrib><creatorcontrib>Raida, Manfred R.</creatorcontrib><creatorcontrib>Taddei, Kevin</creatorcontrib><creatorcontrib>Gandy, Sam</creatorcontrib><creatorcontrib>Masters, Colin L.</creatorcontrib><creatorcontrib>Chatterjee, Pratishtha</creatorcontrib><creatorcontrib>Martins, Ralph N.</creatorcontrib><creatorcontrib>AIBL Research Group</creatorcontrib><creatorcontrib>the AIBL Research Group</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neurochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pedrini, Steve</au><au>Doecke, James D.</au><au>Hone, Eugene</au><au>Wang, Penghao</au><au>Thota, Rohith</au><au>Bush, Ashley I.</au><au>Rowe, Christopher C.</au><au>Dore, Vincent</au><au>Villemagne, Victor L.</au><au>Ames, David</au><au>Rainey‐Smith, Stephanie</au><au>Verdile, Giuseppe</au><au>Sohrabi, Hamid R.</au><au>Raida, Manfred R.</au><au>Taddei, Kevin</au><au>Gandy, Sam</au><au>Masters, Colin L.</au><au>Chatterjee, Pratishtha</au><au>Martins, Ralph N.</au><aucorp>AIBL Research Group</aucorp><aucorp>the AIBL Research Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume</atitle><jtitle>Journal of neurochemistry</jtitle><addtitle>J Neurochem</addtitle><date>2022-10</date><risdate>2022</risdate><volume>163</volume><issue>1</issue><spage>53</spage><epage>67</epage><pages>53-67</pages><issn>0022-3042</issn><eissn>1471-4159</eissn><abstract>Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low‐Density Lipoprotein (LDL) cholesterol. On the other hand, High‐Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL‐functionality, which depends upon the HDL‐cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL‐cargo (Cholesterol, ApoA‐I, ApoA‐II, ApoC‐I, ApoC‐III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC‐Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA‐I ratio in AD and HC‐Conv, as well as an increased ApoD/ApoA‐I ratio and a decreased ApoA‐II/ApoA‐I ratio in AD. Higher cholesterol/ApoA‐I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA‐II/ApoA‐I and ApoJ/ApoA‐I ratios were associated with greater cortical grey matter volume (and for ApoA‐II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status‐independent manner, the ApoE/ApoA‐I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
Remodeling of high‐density lipoprotein (HDL) during disease onset and progression, in which cholesterol and Apolipoprotein D levels are increased while Apolipoprotein A‐II levels are decreased on HDL (left). Additionally, increased cholesterol levels on HDL are associated with increased ventricular volume and decreased grey matter volume, while increased levels of Apolipoprotein A‐II and Apolipoprotein J are associated with increased hippocampal and grey matter volume and reduced ventricular volume (right).</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36000528</pmid><doi>10.1111/jnc.15681</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-2863-0293</orcidid><orcidid>https://orcid.org/0000-0001-6708-3718</orcidid><orcidid>https://orcid.org/0000-0001-8259-9069</orcidid><orcidid>https://orcid.org/0000-0003-3072-7940</orcidid><orcidid>https://orcid.org/0000-0003-4877-1958</orcidid><orcidid>https://orcid.org/0000-0002-6409-8022</orcidid><orcidid>https://orcid.org/0000-0003-2475-0124</orcidid><orcidid>https://orcid.org/0000-0001-7328-9624</orcidid><orcidid>https://orcid.org/0000-0001-8017-8682</orcidid><orcidid>https://orcid.org/0000-0002-8106-7957</orcidid><orcidid>https://orcid.org/0000-0002-8051-0558</orcidid><orcidid>https://orcid.org/0000-0002-0293-913X</orcidid><orcidid>https://orcid.org/0000-0003-3910-2453</orcidid><orcidid>https://orcid.org/0000-0002-4828-9363</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3042 |
ispartof | Journal of neurochemistry, 2022-10, Vol.163 (1), p.53-67 |
issn | 0022-3042 1471-4159 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9804612 |
source | MEDLINE; Access via Wiley Online Library; IngentaConnect Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Free Full-Text Journals in Chemistry |
subjects | Alzheimer Disease Alzheimer's disease Amyloidosis amyloid‐β ApoE Apolipoprotein A-I - metabolism Apolipoprotein A-II - metabolism Apolipoprotein C-III - metabolism Apolipoprotein E Apolipoprotein E4 - metabolism Apolipoproteins E - metabolism Brain Brain - metabolism Cargo Cholesterol Cholesterol - metabolism Cognitive ability Density HDL HDL‐cargo High density lipoprotein Hippocampus Humans Lipoproteins Lipoproteins, HDL - metabolism Lipoproteins, LDL - metabolism Low density lipoprotein Neurodegenerative diseases Original ORIGINAL ARTICLES Patients Substantia grisea Ventricle |
title | Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T13%3A39%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20high%E2%80%90density%20lipoprotein%20cargo%20is%20altered%20in%20Alzheimer's%20disease%20and%20is%20associated%20with%20regional%20brain%20volume&rft.jtitle=Journal%20of%20neurochemistry&rft.au=Pedrini,%20Steve&rft.aucorp=AIBL%20Research%20Group&rft.date=2022-10&rft.volume=163&rft.issue=1&rft.spage=53&rft.epage=67&rft.pages=53-67&rft.issn=0022-3042&rft.eissn=1471-4159&rft_id=info:doi/10.1111/jnc.15681&rft_dat=%3Cproquest_pubme%3E2718476613%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718476613&rft_id=info:pmid/36000528&rfr_iscdi=true |